医薬品リファレンス
Sparsentan
Sparsentan is a medicine in the class genitourinary. It is used for nephropathy.
- 薬効分類: Genitourinary
- 効能・効果: nephropathy
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Genitourinary
- ATCコード
- C09XX01
- 一般的な剤形
- 錠剤
- 既知の相互作用
- 139 (併用禁忌: 24 · 重大: 30 · 中等度: 68 · 軽度: 17)
- 商品名
- 2
- 国・市場
- 2
何に使われるか
作用のしくみ
Single molecule that antagonizes the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R), both thought to be involved in the pathogenesis of IgAN and FSGS.
成人の通常用量（添付文書の要約）
IgAN (adults): start 200 mg orally once daily; after 14 days increase to 400 mg once daily, as tolerated
妊娠と授乳
- 妊娠
- Unsafe Contraindicated in pregnancy: in rats it caused craniofacial and skeletal malformations and fetal death at 10 times human exposure (endothelin and angiotensin blockade). Exclude pregnancy before and during treatment; use effective contraception until 1 month (EU) or 2 weeks (US) after stopping.
- 授乳
- Unknown No human milk data. US label: do not breastfeed (possible infant low blood pressure); EU: should not be used while breastfeeding. LactMed has no data and repeats the maker's advice. Prefer not to breastfeed during treatment.
報告されている副作用
- Hyperkalemia
- Hypotension (including orthostatic hypotension)
- Peripheral edema
- Dizziness
- Anemia
- Acute kidney injury
警告（枠囲み警告）
- Hepatotoxicity: available only through the restricted FILSPARI REMS. Aminotransferase elevations of at least 3-times ULN occurred in up to 3.5% of patients. Measure transaminases and bilirubin before treatment and every 3 months; interrupt and monitor if above 3-times ULN. Generally avoid in patients with baseline aminotransferases above 3-times ULN.
禁忌
- Pregnancy
- Concomitant use with ARBs, ERAs, or aliskiren
注意が必要な方
- Hepatotoxicity: monitor aminotransferases and bilirubin; stop and seek medical attention if symptoms of liver injury occur.
- Hypotension: consider adjusting other antihypertensives; consider dose reduction or interruption if it develops.
- Acute kidney injury: monitor kidney function periodically; patients with renal artery stenosis, CKD, severe heart failure or volume depletion are at particular risk.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (139)
- Aliskiren + Sparsentan Contraindicated
- Amlodipine-hydrochlorothiazide-valsartan + Sparsentan Contraindicated
- Amlodipine-olmesartan + Sparsentan Contraindicated
- Amlodipine-olmesartan-hydrochlorothiazide + Sparsentan Contraindicated
- Amlodipine-valsartan + Sparsentan Contraindicated
- Azilsartan + Sparsentan Contraindicated
- Azilsartan-chlorthalidone + Sparsentan Contraindicated
- Bosentan + Sparsentan Contraindicated
- Candesartan + Sparsentan Contraindicated
- Candesartan-hydrochlorothiazide + Sparsentan Contraindicated
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Sparsentanの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
- IV preparation and dilution
WebでPro+を14日間無料でお試し。カード登録不要。
よくある質問
What is Sparsentan used for?
Sparsentan is a medicine in the class genitourinary. It is used for Nephropathy.
What side effects have been reported with Sparsentan?
Hyperkalemia, Hypotension (including orthostatic hypotension), Peripheral edema, Dizziness, Anemia, Acute kidney injury. Serious warning: Hepatotoxicity: available only through the restricted FILSPARI REMS.
Can Sparsentan be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Contraindicated in pregnancy: in rats it caused craniofacial and skeletal malformations and fetal death at 10 times human exposure (endothelin and angiotensin blockade). Exclude pregnancy before and during treatment; use effective contraception until 1 month (EU) or 2 weeks (US) after stopping. Breastfeeding: Unknown. No human milk data. US label: do not breastfeed (possible infant low blood pressure); EU: should not be used while breastfeeding. LactMed has no data and repeats the maker's advice. Prefer not to breastfeed during treatment.
What does Sparsentan interact with?
MediHelp lists 139 known interactions for Sparsentan. Contraindicated: 24 · Major: 30 · Moderate: 68 · Minor: 17. The most serious include Aliskiren, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
